Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group. Fisher BA, et al. Among authors: papas a. Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
Fisher BA, Szanto A, Ng WF, Bombardieri M, Posch MG, Papas AS, Farag AM, Daikeler T, Bannert B, Kyburz D, Kivitz AJ, Carsons SE, Isenberg DA, Barone F, Bowman SJ, Espié P, Floch D, Dupuy C, Ren X, Faerber PM, Wright AM, Hockey HU, Rotte M, Milojevic J, Avrameas A, Valentin MA, Rush JS, Gergely P. Fisher BA, et al. Among authors: papas as. Lancet Rheumatol. 2020 Mar;2(3):e142-e152. doi: 10.1016/S2665-9913(19)30135-3. Epub 2020 Jan 23. Lancet Rheumatol. 2020. PMID: 38263652
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation.
Gordon RA, Nguyen Y, Foulquier N, Beydon M, Gheita TA, Hajji R, Sahbudin I, Hoi A, Ng WF, Mendonça JA, Wallace DJ, Shea B, Bruyn GA, Goodman SM, Fisher BA, Baldini C, Torralba KD, Bootsma H, Akpek EK, Karakus S, Baer AN, Chakravarty SD, Terslev L, D'Agostino MA, Mariette X, DiRenzo D, Rasmussen A, Papas A, Montoya C, Arends S, Yusof MYM, Pintilie I, Warner BM, Hammitt KM, Strand V, Bouillot C, Tugwell P, Inanc N, Andreu JL, Wahren-Herlenius M, Devauchelle-Pensec V, Shiboski CH, Benyoussef A, Masli S, Lee AYS, Cornec D, Bowman S, Rischmueller M, McCoy SS, Seror R. Gordon RA, et al. Among authors: papas a. Semin Arthritis Rheum. 2024 Apr;65:152378. doi: 10.1016/j.semarthrit.2024.152378. Epub 2024 Jan 23. Semin Arthritis Rheum. 2024. PMID: 38310657
CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.
St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W, Pham TH, Sikora K, Rees WA, Alevizos I. St Clair EW, et al. Among authors: papas a. Nat Med. 2024 Jun;30(6):1583-1592. doi: 10.1038/s41591-024-03009-3. Epub 2024 Jun 5. Nat Med. 2024. PMID: 38839899 Free PMC article. Clinical Trial.
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W. Dörner T, et al. Among authors: papas a. Arthritis Rheumatol. 2024 Nov 18. doi: 10.1002/art.43059. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39557617
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, Hanser M, Abdallah N, Grioni A, Santos Da Costa A, Ferrero E, Gergely P, Hillenbrand R, Avrameas A, Cenni B, Siegel RM. Dörner T, et al. Among authors: papas as. Ann Rheum Dis. 2024 Feb 15;83(3):360-371. doi: 10.1136/ard-2023-224691. Ann Rheum Dis. 2024. PMID: 37932009 Free PMC article. Clinical Trial.
Letter comments on "Advanced reconstructive techniques following orbital exenteration: The role of LCFA free flaps." Temporalis muscle flap: A simple yet reliable alternative for orbital exenteration reconstruction.
Karamitros G, Papas A, Lykoudis E, Grant MP, Lamaris GA. Karamitros G, et al. Among authors: papas a. J Plast Reconstr Aesthet Surg. 2025 Jan 8;101:192-195. doi: 10.1016/j.bjps.2025.01.003. Online ahead of print. J Plast Reconstr Aesthet Surg. 2025. PMID: 39799789 No abstract available.
182 results